TUFTS Center for the Study of Drug Development TUFTS CSDD INSIDER APRIL 2021

From the Director



Dear CSDD Friends:

At a global conference I was recently asked — given CSDD's rich and growing knowledge about protocol design and clinical trial performance — if Lasagna's Law still applies. The question gave me pause. Our research suggests that the Law – which holds that the incidence of patient availability decreases when a clinical trial begins and returns when a clinical trial ends – remains universally true, but

its explanation is deeper.

Dr. Louis Lasagna – founder of Tufts CSDD and a recognized thought leader and pioneer in clinical pharmacology and the science of drug regulation — originally attributed the 'Law' to the observed over-optimism of investigative site patient accrual forecasting. Narrow eligibility criteria was considered the primary cause of the mis-estimation.

Tufts CSDD study findings indicate that research professionals under-estimate several factors: (1) the role that the burden of disease plays; (2) patient perceptions of the demands of protocol adherence; and (3) the commitment of treating nurses and physicians to facilitate and enable participation in clinical trials. And these three essential factors each vary widely by demographic and disease subgroups.

Current and upcoming Tufts CSDD grant-funded research studies are helping to further quantify the impact of factors that ultimately drive recruitment and retention challenges. Also this month we are fielding a global survey assessing the diversity of the investigative site landscape and variation in familiarity and experience participating in clinical trials. We are currently conducting a detailed evaluation of the diversity of participants in pivotal trials supporting recent drugs and biologics approved by the European Medicines Agency.

Last month Tufts CSDD received strong interest in our new algorithm assigning participant burden scores based on protocol design characteristics. In response, during April we are launching a workshop for sponsor companies to apply the algorithm to prospective protocol design activity.

This Insider highlights a number of exciting and important ongoing and newly launched initiatives including not only grant-funded studies but also new professional development courses offered this spring and fall. Please reach out if you are interested in learning more. And as always, we welcome your feedback.

Kenneth Getz Director and Professor



Roundtables

Join us on May 17 for a virtual roundtable on ICH E6 R2.

Drug development executives and regulatory agency representations will come together to discuss ICH E6 R2 implementation challenges and solutions and to explore ways to accommodate changing clinical research operating models some facilitated by the pandemic. Space is



limited to promote highly active and engaged roundtable discussion. For more information, **contact Sundé Daniels**.

Working Group Studies



Join Our Working Group Study Characterizing and Improving the Innovation Adoption Process

Tufts CSDD has initiated a new working group study looking at how sponsor companies adopt innovations supporting drug development planning, design,

execution, data management and logistics. The study will characterize best practices including those associated with pandemic response; apply lessons learned from other heavily regulated industries; and identify opportunities to accelerate innovation adoption. **Contact us for more information**.

Global Surveys

Participate in the Tufts CSDD Global Study on Investigative Site Diversity

Tufts CSDD is conducting an ambitious, first-of-its-kind global study mapping and examining the demographic diversity of the global investigative site landscape. The goal of the study is to inform new strategies and practices that will enable sponsors and CROs to more successfully partner with investigative sites. We encourage site professionals to participate. **Complete the CSDD Survey.**



Professional Development Courses



May 12, 2021

Grab n' Go course: Enhancing Productivity and Performance of Remote or Distributed Teams (Online)

Designed for professionals with very tight schedules, this half-day program focuses on critical leadership skills and management practice development. All Grab n' Go courses combine lecture and small group discussion to generate actionable ideas and insights that can be put into practice immediately. Class sizes are limited. For more information, **contact Sundé Daniels**.



June 9, 16, 23 & 30, 2021

Summer Leadership for Drug Development Teams (Online)

This more in-depth course is designed to build leadership skills, improve cross-functional performance and enhance R&D productivity. Delegates meet online in large and small groups over the course of four weeks beginning in early June. For more information, **contact Sundé Daniels**.

Research Highlights

Our Latest *Impact Report*



Planned and unplanned mid-study updates challenge clinical trial timelines

elays for mid-study updates longer for larger pharmaceutical companies

- Data management cycle times for start-up and close-out activity have not changed since 2017.
 Mid much update and extend output fluxed extensional and the test of a line of a start of a line of a start of a start
- Mid-study updates and system flexibility and customization are the top challenges cited with electronic data capture (EDC) capabilities.
- Each planned and unplanned mid-study update typically takes approximately 30 days to complete before the study can resume or go-live again.
- Companies report an average of four planned and four unplanned mid-study updates per clinical trial, with very high variance.
- Planned mid-study updates on average take 1.5 days less time to go-live again, compared to unplanned mid-study updates.
- Sponsor companies overall are satisfied with the capabilities of their EDC systems.

Planned and Unplanned Mid-study Updates Challenge Clinical Trial Timelines

Our March/April 2021 *Tufts CSDD Impact Report* presents results of recent research examining how the clinical data management function is managing unprecedented challenges as clinical trial data volume and data diversity continue to grow.

Learn more | Purchase online

Coming in Early May:

Development Performance by Company Size

Order your copy today!



Individual subscription | Corporate subscription

Recent Publications

Getz K. Characterizing White Space in the Quest to Drive Development Speed. *Applied Clinical Trials*, 2021; April 7. Access article

Florez M, and Getz K. Anticipating digital transformation of the drug development workforce. Pharmaceutical Executive, March 26. Access article

Getz K. **Public Trust and the 'Last Mile' for COVID-19 Vaccines.** Applied Clinical Trials 2020; 29 (12): 11 – 12. Access article

Gottlieb, N, Byrne, J, Getz, K. Investigative Site Placement Practices to Support Operation Warp Speed. *Applied Clinical Trials* 2020; 29 (12): 26-28. Access article

Raj Indupuri, Sheila Rocchio, Kenneth A. Getz, Beth Harper, Michael Wilkinson. **Enabling Digital Transformation: Managing External Clinical Data Sources to Advance Drug Development.** *Applied Clinical Trials* 2020; November 13. Access article

Stephen LeBreton, Mary Jo Lamberti, Adam Dion, Kenneth A. Getz. **COVID-19 and Its Impact on the Future of Clinical Trial Execution.** *Applied Clinical Trials* 2020; October 22. Access article

Galson S, Austin C, Khandekar E, Hudson L, DiMasi J, Califf R, Wagner J. The Failure to Fail


Smartly. Nature Reviews Drug Discovery 2020; September 23. Published online: Access article

Harper B, Wilkinson M, Indupuri R, Rocchio S, Getz, K. **Evolving Clinical Data Strategies and Tactics in Response to Digital Transformation**. *Ther Innov Regul Sci* 2020; September 14. Access article

DiMasi, J.A. Research and Development Costs of New Drugs [Letter to the Editor]. *JAMA* 2020; 324(5):517. Access article

Data Insights Digest

Trends in Phase III Protocol Endpoints



Endpoint Type

- During the past 15 years, the number of core endpoints – those supporting primary and key secondary outcomes, baseline assessments and those supporting regulatory compliance – has more than doubled.
- During that same period, the number of non-core endpoints has more than tripled as sponsor company demand for data supporting exploratory, miscellaneous and tertiary endpoints has intensified.

Subscribe today to get your copy of the Tufts CSDD Impact Report.

Faculty and Staff Presentations

Recent Presentations



Joseph A. DiMasi, PhD American Association of Pharmaceutical Scientists Online | February 4

Leveraging Predictive Dosing to Reduce Clinical Trial Risk

Ken Getz, MBA xTalks Online | February 10

Accelerating Drug Development During the Pandemic -Lessons Learned and Their Implications Ken Getz, MBA







SCOPE Virtual Summit for Clinical Ops Executives Online | March 2

Anticipating Changes in Clinical Trial Design and Execution Post Pandemic

Ken Getz, MBA Clinical Development and Innovation Forum 2021 Online | March 9

New Benchmarks on Protocol Design Practices and Their Impact on Clinical Trial Performance and Efficiency

Michael Wilkinson, MPH, Zak Smith, MS, Ken Getz MBA MCC Study Quality Trailblazer Group Meeting Online | March 10

Upcoming Presentations



Clinical Development and Innovation Forum 2021

临床开发与创新合作论坛2021

New Strategies to Balance Protocol Complexity, Customization and Executional Feasibility Ken Getz, MBA

Reuters Pharma: Clinical 2021 Online | April 7

Taking Patient Centricity to the Next Level

Ken Getz, MBA Patients as Partners Online | April 9

Rapid Innovation in Clinical Research

Ken Getz, MBA Avoca Quality Consortium Online | April 20



Examining Strategic Implications of Pandemic Response on the Global Investigative Site Landscape Ken Getz, MBA SCRS EU Summit Online | April 22

Powered by the Pandemic: How Pharma has Succeeded and How it Will Continue to Embrace Operational Changes Facilitated by COVID-19 Ken Getz, MBA RBQM Live Online | May 20













The Evolving State of Clinical Trial Execution: Pilots or Permanent Change? Ken Getz, MBA ACRP Annual Meeting Online | May 20



Subscriptions, Papers and Books



Purchase Impact Reports



Download White Paper

Become a Corporate Sponsor or donate to support our critical mission of providing data-driven analysis and strategic insight to improve the efficiency and productivity of pharmaceutical development.

About Tufts CSDD

Support Tufts CSDD

Tufts Center for the Study of Drug Development 75 Kneeland Street, Suite 1110 Boston, MA 02111 617-636-2170

